The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) Lymphomas

Caroline A. Heckman, Evonne Mochon, Magdalena Arcinas, Linda M. Boxer

Journal of Biological Chemistry · 1997 · 78 citations · 31 references

DOIFull text

Open access

Concepts

Abstract

The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis. An in vivofootprint over a potential WT1 binding site in the bcl-2 5′-flanking sequence was identified on the normal silent allele. Electrophoretic mobility shift assays with the bcl-2 WT1 site demonstrated a single specific complex. UV cross-linking and Western analysis revealed that this gel shift complex contained WT1 protein. Deletion or mutation of the WT1 site resulted in an increase in activity of the bcl-2 promoter in DHL-4 cells. Cotransfection with a 3:1 ratio of a WT1 expression vector to thebcl-2 promoter construct led to a 3.0-fold repression of the bcl-2 promoter. Cotransfection with a WT1 expression vector and the bcl-2 promoter with the mutated WT1 site resulted in only 1.2-fold repression. We conclude that the WT1 site functions as a negative regulatory site for the normal silentbcl-2 allele in t(14;18) lymphomas. The WT1 site is not occupied on the translocated bcl-2 allele. The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis. An in vivofootprint over a potential WT1 binding site in the bcl-2 5′-flanking sequence was identified on the normal silent allele. Electrophoretic mobility shift assays with the bcl-2 WT1 site demonstrated a single specific complex. UV cross-linking and Western analysis revealed that this gel shift complex contained WT1 protein. Deletion or mutation of the WT1 site resulted in an increase in activity of the bcl-2 promoter in DHL-4 cells. Cotransfection with a 3:1 ratio of a WT1 expression vector to thebcl-2 promoter construct led to a 3.0-fold repression of the bcl-2 promoter. Cotransfection with a WT1 expression vector and the bcl-2 promoter with the mutated WT1 site resulted in only 1.2-fold repression. We conclude that the WT1 site functions as a negative regulatory site for the normal silentbcl-2 allele in t(14;18) lymphomas. The WT1 site is not occupied on the translocated bcl-2 allele. The bcl-2 gene was originally identified by its involvement in the t(14;18) translocation that is associated with human follicular lymphoma (1Yunis J.J. Science. 1983; 221: 227-236Crossref PubMed Scopus (848) Google Scholar). The translocation of bcl-2 to the immunoglobulin heavy chain locus leads to deregulated expression ofbcl-2, and high levels of bcl-2 mRNA are detected in cells with the t(14;18) translocation (2Cleary M.L. Smith S.D. Sklar J. Cell. 1986; 47: 19-28Abstract Full Text PDF PubMed Scopus (1076) Google Scholar, 3Graninger W.B. Seto M. Boutain B. Goldman P. Korsmeyer S.J. J. Clin. Invest. 1987; 80: 1512-1515Crossref PubMed Scopus (246) Google Scholar). It has been shown that the expression of bcl-2 is entirely from the translocated allele and that the normal allele is silent (3Graninger W.B. Seto M. Boutain B. Goldman P. Korsmeyer S.J. J. Clin. Invest. 1987; 80: 1512-1515Crossref PubMed Scopus (246) Google Scholar). Although the mechanism of the deregulation of bcl-2 is unknown, regulatory elements of the immunoglobulin locus may play a role. It is also not known how the normal allele is silenced. The deregulatedbcl-2 gene is believed to play a role in the pathogenesis of follicular lymphoma. Transgenic mice containing abcl-2-immunoglobulin minigene show a polyclonal expansion of B cells with prolonged cell survival but no increase in cell cycling. Progression to high grade lymphomas is seen in these mice (4McDonnell T.J. Korsmeyer S.J. Nature. 1991; 349: 254-256Crossref PubMed Scopus (764) Google Scholar). The major transcriptional promoter for bcl-2 in B cells, P1, is located 1386–1423 base pairs upstream of the translation start site (5Seto M. Jaeger U. Hockett R.D. Graninger W. Bennett S. Goldman P. Korsmeyer S.J. EMBO J. 1988; 7: 123-131Crossref PubMed Scopus (457) Google Scholar). This is a TATA-less, GC-rich promoter that displays multiple start sites. A minor promoter, P2, utilized in some cell types, is located 1.3 kilobases downstream from the first one (5Seto M. Jaeger U. Hockett R.D. Graninger W. Bennett S. Goldman P. Korsmeyer S.J. EMBO J. 1988; 7: 123-131Crossref PubMed Scopus (457) Google Scholar). Several negative regulatory sites have been described in the bcl-2 promoter region. One of these negative regulatory elements, is located upstream of the P2 promoter (6Young R.L. Korsmeyer S.J. Mol. Cell. Biol. 1993; 13: 3686-3697Crossref PubMed Scopus (182) Google Scholar). The proteins that bind to this element have not been identified, although p53 was shown to mediate down-regulation ofbcl-2 either directly or indirectly through a 195-base pair segment of this region (7Miyashita T. Harigai M. Hanada M. Reed J.C. Cancer Res. 1994; 54: 3131-3135PubMed Google Scholar). We have previously described three π1 binding sites, which are negative regulators of bcl-2 expression in pre-B cells (8Chen H.-M. Boxer L.M. Mol. Cell. Biol. 1995; 15: 3840-3847Crossref PubMed Google Scholar). Normal pre-B cells express very littlebcl-2, and extensive cell death by apoptosis occurs at this developmental stage. Levels of Bcl-2 protein are increased in mature B cells. We have found that the three π1 sites are not functional in mature B cells (8Chen H.-M. Boxer L.M. Mol. Cell. Biol. 1995; 15: 3840-3847Crossref PubMed Google Scholar). Repression of the bcl-2 promoter by the WT1 protein in HeLa cells has been described recently (9Hewitt S.M. Hamada S. McDonnell T.J. Rauscher F.J.I. Saunders G.F. Cancer Res. 1995; 55: 5386-5389PubMed Google Scholar). There are several potential WT1 binding sites in the bcl-2 promoter, and it is not clear whether all of them are functional. We have recently characterized the regulatory regions, including a cAMP-responsive element (CRE), 1The abbreviations used are: CRE, cAMP-responsive element; PCR, polymerase chain reaction; IGF-II, insulin-like growth factor II; EMSA, electrophoretic mobility shift assay. that are responsible for the positive regulation of bcl-2 expression during B-cell activation in mature B cells and during rescue from calcium-dependent apoptosis of immature B cells (10Wilson B.E. Mochon E. Boxer L.M. Mol. Cell. Biol. 1996; 16: 5546-5556Crossref PubMed Scopus (377) Google Scholar). We have found that a CRE element mediates the increase in bcl-2 expression following surface immunoglobulin cross-linking in mature B cells or treatment with phorbol esters in both mature and immature B cells. We are studying in vivo protein binding to both the normal and translocated bcl-2 alleles in follicular lymphoma cells with a t(14;18) translocation. We identified an in vivofootprint at a CRE site in the 5′-flanking sequence of the translocatedbcl-2 gene, and we demonstrated that CREB family proteins bound to this site in vitro and that the maximal increase inbcl-2 promoter expression mediated by the immunoglobulin heavy chain gene enhancers in transient transfection experiments was dependent on the CRE site (11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). These results suggest that the CRE site functions as a positive regulatory element for the translocatedbcl-2 allele in follicular lymphoma with the t(14;18) translocation. We now describe an in vivo footprint over a potential WT1 site on the normal bcl-2 allele; this site is not occupied on the translocated allele. The putative Wilms' tumor suppressor gene (wt1) encodes a zinc finger DNA binding protein that functions as a transcriptional repressor (12Rauscher R.J.I. Morris J.F. Tournay O.E. Cook D.M. Curran T. Science. 1990; 250: 1259-1263Crossref PubMed Scopus (471) Google Scholar, 13Madden S.L. Cook D.M. Morris J.F. Gashler A. Sukhatme V.P. Rauscher III., R.J. Science. 1991; 253: 1550-1553Crossref PubMed Scopus (409) Google Scholar). The WT1 protein binds to the target sequence GNGNGGGNG, which is also recognized by the zinc finger transcription factors EGR-1, EGR-2, and EGR-3. The gene for WT1 is mainly expressed in the developing kidney, testis, ovary, and spleen (14Pritchard-Jones K. Fleming S. Davidson D. Bickmore W. Porteous D. Gosden C. Bard J. Buckler A. Pelletier J. Housman D. Heyningen V.V. Hastie N. Nature. 1990; 346: 194-197Crossref PubMed Scopus (769) Google Scholar). Recent evidence suggests that the WT1 protein may play an important role in hematopoiesis, since it is expressed in immature hematopoietic cells and also in acute myeloid, acute lymphoblastic, and chronic myeloid leukemia cells (15Fraizer G.C. Patmasiriwat P. Zhang X. Saunders G.F. Blood. 1995; 86: 4704-4706Crossref PubMed Google Scholar, 16Inoue K. Sugiyama H. Ogawa H. Nakagawa M. Yamagami T. Miwa H. Kita K. Hiraoka A. Masaoka T. Nasu K. Kyo T. Dohy H. Nakauchi H. Ishidate T. Akiyama T. Kishimoto T. Blood. 1994; 84: 3071-3079Crossref PubMed Google Scholar, 17Inoue K. Ogawa H. Sonoda Y. Kimura T. Sakabe H. Oka Y. Miyake S. Tamaki H. Oji Y. Yamagami T. Tatekawa T. Soma T. Kishimoto T. Sugiyama H. Blood. 1997; 89: 1405-1412Crossref PubMed Google Scholar). The erythrocyte/megakaryocyte transcription factor GATA-1 is a positive regulator of WT1 expression in certain hematopoietic cells (18Wu Y. Fraizer G.C. Saunders G.F. J. Biol. Chem. 1995; 270: 5944-5949Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar). In this study, we show that WT1 protein binds to a consensus binding site in the bcl-2 promoter and that cotransfection of a WT1 expression vector decreases expression from the bcl-2 promoter. The presence of the immunoglobulin 3′-enhancers abrogates the repression by WT1. The bcl-2-promoter-luciferase constructs have been described previously (10Wilson B.E. Mochon E. Boxer L.M. Mol. Cell. Biol. 1996; 16: 5546-5556Crossref PubMed Scopus (377) Google Scholar, 11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). A construct with a mutated WT1 site was generated from the −1640 construct using a technique described by Higuchi (19Higuchi R. Innis M.A. Gelfand D.H. Sninsky J.J. White T.J. Recombinant PCR. PCR Protocols: A Guide to Methods and Applications. Academic Press, Inc., San Diego1990: 177-183Google Scholar). The oligonucleotide sequence used for the PCR primer is (mutated bases are in boldface and the WT1 site is underlined): CCCCTTCCTAATGCGCCCGCCC. All plasmid sequences were confirmed by the dideoxynucleotide method (Sequenase, U. S. Biochemical). The WT1 expression vector consisted of the full-length coding region of the gene under the control of the cytomegalovirus immediate-early promoter (20Patwardhan S. Gashler A. Siegel M.G. Chang L.C. Joseph L.J. Shows T.B. LeBeau M.M. Sukhatme V.P. Oncogene. 1991; 6: 917-928PubMed Google Scholar). DHL-4 cells were cultured in RPMI medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mml-glutamine. This cell line has a t(14;18) translocation. DNA transfections were performed with cells in log phase (5–6 × 105 cells/ml). The cells were washed with RPMI and resuspended at 3 × 107 cells/ml in RPMI medium containing 25 μg/ml DEAE-dextran (21Gauss G.H. Lieber M.R. Nucleic Acids Res. 1992; 20: 6739-6740Crossref PubMed Scopus (43) Google Scholar). A total of 10–20 μg of plasmid DNA was added, and electroporation was performed with a Bio-Rad Gene Pulser at 960 microfarads and 320 mV. Transfected cells were cultured in 25 ml of supplemented RPMI medium for 48 h. Reporter gene activity was determined by the luciferase assay system (Promega), and luminescence was quantitated with an LKB 1251 luminometer. Variation in transfection efficiency was controlled for by cotransfection with 5 μg of a Rous sarcoma virus long terminal repeat-β-galactosidase plasmid. Each assay was performed at least three times in duplicate with at least two different plasmid preparations. The normalized average values with standard deviations were plotted. DHL-4 cells were embedded in agarose plugs, lysed with detergent, and treated with proteinase K as described (22Zelenetz A. Chu G. Galili N. Bangs C.D. Horning S.J. Donton T.A. Cleary M.L. Levy R. Blood. 1991; 78: 1552-1560Crossref PubMed Google Scholar). NotI digestion was performed, and the samples were separated on a 1% agarose gel in 0.5 × Tris borate-EDTA for 23 h at 160 V (5.5 V/cm) at room temperature with a pulse time of 55 s. The translocated bcl-2 gene yields a 520-kilobase band (11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). Treatment of cells with dimethyl sulfate was performed as described previously (23Arcinas M. Boxer L.M. Oncogene. 1994; 9: 2699-2706PubMed Google Scholar, 24Ji L. Arcinas M. Boxer L.M. Mol. Cell. Biol. 1994; 14: 7967-7974Crossref PubMed Google Scholar). After electrophoresis of the DNA, one lane of the gel was transferred to a filter; a probe forbcl-2, pFL1 (25Cleary M.L. Sklar J. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 7439-7443Crossref PubMed Scopus (833) Google Scholar), and a probe for JH (26Ravetch J.V. Siebenlist U. Korsmeyer S. Waldmann T. Leder P. Cell. 1981; 27: 583-591Abstract Full Text PDF PubMed Scopus (767) Google Scholar) were used sequentially to locate the two bcl-2 alleles. The DNA in these two regions was eluted from the gel. Cleavage with piperidine was performed according to the Maxam-Gilbert procedure (27Maxam A. Gilbert W. Methods Enzymol. 1980; 65: 499-560Crossref PubMed Scopus (9013) Google Scholar). Chemically modified and cleaved DNA was then subjected to amplification by ligation-mediated PCR essentially as described by Mueller and Wold (28Mueller P.R. Wold B. Science. 1989; 246: 780-786Crossref PubMed Scopus (798) Google Scholar), Pfeifer et al. (29Pfeifer G. Steigerwald S.D. Mueller P.R. Wold B. Riggs A.D. Science. 1989; 246: 810-813Crossref PubMed Scopus (309) Google Scholar), and Garrity and Wold (30Garrity P. Wold B. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 1021-2025Crossref PubMed Scopus (202) Google Scholar). Sequenase was used for first strand synthesis, and DNA polymerase was used for PCR. used for amplification were for 2 for 2 and for 3 After of PCR, samples were with of primer and by one of PCR. The were in a gel. The used for PCR were on oligonucleotide The used were and The for the coding strand were and The strand were and of was performed as described previously (23Arcinas M. Boxer L.M. Oncogene. 1994; 9: 2699-2706PubMed Google Scholar) with values of were and were not as The used for of the WT1 region are shown with the WT1 site and the mutated bases in The WT1 site in the insulin-like growth factor promoter was used as a positive control P. S.L. Rauscher F.J.I. Sukhatme V.P. Mol. Cell. Biol. 1994; 14: PubMed Scopus Google The were with and with and were as 0.5 2 μg of of oligonucleotide and μg of protein from and were in all were in the presence or of for at room was performed at at in a 0.5 × Tris borate-EDTA gel. the μg of an specific for a region the of WT1 from or an specific for a region the of WT1 from was used in with the was performed as described UV cross-linking was performed as described previously R. Smith K. in Scholar) with a UV at for An of the gel was used to locate the of the gel containing the were and the were eluted at room temperature in sulfate 5 and The eluted protein was with of washed with and After in gel electrophoresis was The proteins were by The was used for Western The WT1 and are described The translocated and normal bcl-2 alleles from DHL-4 cells were separated by pulsed field electrophoresis as described previously (11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). PCR was performed on primer that a region of the bcl-2 5′-flanking we found a footprint located on the normal bcl-2 allele that was not on the translocated bcl-2 allele were on the coding and demonstrated on the The sequence is to the WT1 consensus Although are several potential WT1 sites in the bcl-2 promoter, we found of only one of these sites. A oligonucleotide that the sequence was used in were with thebcl-2 WT1 oligonucleotide lane with oligonucleotide demonstrated that only the complex was specific 2 2 and A of the mutated WT1 oligonucleotide not the specific complex 2 lane The mutated WT1 oligonucleotide not the specific complex 2 with the site was performed in to whether the protein bound to the bcl-2 WT1 site and the shown in 2 the site with thebcl-2 WT1 site for protein The bcl-2 WT1 site also with the site for protein binding 2 experiments were performed with that either a region the of the WT1 protein or a region the of WT1. shown in 2 B the specific complex was in in the presence of the the of and a complex was The of the the of WT1 a in the of the specific but no complex was lane It is that this with binding of WT1 to DNA since the DNA binding is located the the proteins that bind to the bcl-2 WT1 UV cross-linking by gel electrophoresis was performed with the specific complex UV cross-linking a protein of for bound oligonucleotide a protein of 3 lane Western analysis was performed on the UV protein with an a region the of WT1. shown in B the protein in this complex with an WT1. In a protein of was also this was protein that was in the complex. a of the of the protein in this Western analysis UV cross-linking was A protein of of was 3 lane the Western analysis of the UV protein was performed with an a region the of the protein were seen lane with lane protein or protein with either WT1 was the region of the gel from with the mutated WT1 site was lane these one conclude that WT1 not with the complex during electrophoresis through the gel. whether the WT1 site in thebcl-2 functional transient transfection experiments were The constructs for the transient transfection experiments are in A. shown in of the bcl-2 WT1 site resulted in an increase in activity of The activity of these constructs of the bcl-2 was the positive regulatory region been the of the WT1 site in the of the full-length promoter, a mutation was in this of the WT1 site resulted in a increase in promoter activity with the full-length promoter whether WT1 was the transcription cotransfection experiments were of a WT1 expression vector with the full-length bcl-2 promoter resulted in a in activity at a ratio and a 3.0-fold at a 3:1 ratio of WT1 to bcl-2 construct 5 The of this repression was mediated through the single WT1 site mutation of this site in the bcl-2 promoter resulted in a of repression of the promoter. a 3:1 the activity was by 1.2-fold 5 of regions of the immunoglobulin gene to the bcl-2 construct in resulted in a increase in activity We to whether mutation of the WT1 site to a increase in activity in the presence of the immunoglobulin The WT1 site was and transient transfection experiments were performed in DHL-4 cells. shown in was no in the bcl-2 promoter activity the WT1 site was mutated in the presence of the immunoglobulin We also the of cotransfection of a WT1 expression vector on the bcl-2 promoter activity in the presence of the immunoglobulin at a ratio of 3:1 WT1 expression vector to the was no in the bcl-2 promoter activity These results suggest that the immunoglobulin enhancers the activity or of the WT1 site in thebcl-2 promoter. In vivo has been used to a region in the bcl-2 promoter that is occupied on the silent normal allele but not on the translocated allele. We have shown by several different that the WT1 protein binds to this site in were with with thebcl-2 WT1 the complex was and it contained a protein of as demonstrated by UV cross-linking Western analysis that this protein with two WT1. The WT1 site of the promoter for binding in with the bcl-2 WT1 We have shown that the WT1 site has functional activity in DHL-4 cells. Deletion or mutation of this site resulted in an increase inbcl-2 promoter Cotransfection with a WT1 expression vector the bcl-2 promoter and the of the repression was by mutation of the WT1 site in the bcl-2 promoter. Although WT1 and bind to DNA we that the in vivo footprint we is to since it is associated with negative regulatory activity and cotransfection with an expression vector no on bcl-2 promoter Mochon and L. M. it is that also bind to this site in vivo and bcl-2 promoter et al. (9Hewitt S.M. Hamada S. McDonnell T.J. Rauscher F.J.I. Saunders G.F. Cancer Res. 1995; 55: 5386-5389PubMed Google Scholar) described repression of thebcl-2 promoter by WT1 in cotransfection experiments in HeLa cells. are several potential WT1 sites in thebcl-2 promoter, it was not clear which site or sites mediated this repression. We found an in vivo footprint over a single WT1 site on the normal bcl-2 allele. with cotransfection of WT1 and mutation of this site suggest at least in DHL-4 cells, this is the major functional In transient transfection we that the WT1 site in the bcl-2 promoter demonstrated activity in the presence of the immunoglobulin heavy chain gene of this site not to an increase in bcl-2 promoter In cotransfection experiments with a WT1 expression we were not to repression of thebcl-2 promoter in the presence of the immunoglobulin These and the results of the in suggest that the presence of the immunoglobulin enhancers repression of the bcl-2 promoter by WT1. It is that the activity of the WT1 protein is by the immunoglobulin for the bound to the enhancers may to the repression of WT1. It is to that two tumor suppressor gene WT1 and have been shown to the bcl-2 promoter. These are or mutated in and this may to increased bcl-2 expression and an increased to WT1 protein is expressed in the DHL-4 cell and it in the repression of the normal bcl-2 it has no on the translocated allele. We have shown that the CRE site in the bcl-2 promoter functions as a positive regulatory element in transfection (10Wilson B.E. Mochon E. Boxer L.M. Mol. Cell. Biol. 1996; 16: 5546-5556Crossref PubMed Scopus (377) Google Scholar), and we that it is in the expression of the translocated bcl-2 allele in t(14;18) lymphomas. This site is occupied on the translocated bcl-2 allele and not on the normal as by in vivo (11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). It is that the deregulation of the translocated bcl-2 allele is a of the bcl-2 promoter region and regulatory elements of the immunoglobulin we have demonstrated that several of the immunoglobulin heavy chain enhancers increase bcl-2 promoter activity and that the maximal increase is dependent on an bcl-2 CRE site (11Ji L. Mochon E. Arcinas M. Boxer L.M. J. Biol. Chem. 1996; 271: 22687-22691Abstract Full Text Full Text PDF PubMed Scopus (71) Google Scholar). We now show that a WT1 site is occupied on the normal silent bcl-2 allele and that it functions as a negative regulatory This site to have activity in the presence of the immunoglobulin We are the the transcription factors that bind the immunoglobulin enhancers and the transcription factors that bind to the translocated bcl-2 promoter in t(14;18) lymphoma cells.

References

31